COMP <GO>
LIMN vs SCNI // EV/EBITDA & P/E VALUATION
Liminatus Pharma Inc. (Class A) (NASDAQ) VS. Scinai Immunotherapeutics Ltd. (NASDAQ) • 15-METRIC TALLY: LIMN 2
— SCNI 1
■ METRIC PARITY
LAST: $2.90 (-0.86%) • MKT CAP: $3.9M
valuation
—
LAST: $0.52 (-2.92%) • MKT CAP: $1.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIMN VS. SCNI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIMN | SCNI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | -30.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 99.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | SCNI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.4 | 22.7 | +11.75 | LIMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.9M | $1.4M | $2.5M | LIMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIMN REV | SCNI REV | LIMN GROSS % | SCNI GROSS % | LIMN FCF | SCNI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.3M | — | -50.0% | -$10.0M | -$6.1M |
| FY 2024 | $0 | $658.0K | — | -50.0% | -$1.5M | -$6.3M |
| FY 2023 | — | $0 | — | — | — | -$9.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIMN // BETA —
SCNI // BETA —